A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
Nature, Published online: 05 February 2025; doi:10.1038/s41586-024-08507-5A phase I trial of a neoantigen-targeting personalized cancer vaccine led to durable and polyfunctional T cell responses and antitumour recognition, and was associated with no recurrence in patients with high-risk clear cell renal cell carcinoma.
![A neoantigen vaccine generates antitumour immunity in renal cell carcinoma](https://media.springernature.com/m685/springer-static/image/art:10.1038%2Fs41586-024-08507-5/MediaObjects/41586_2024_8507_Fig1_HTML.png)
Nature, Published online: 05 February 2025; doi:10.1038/s41586-024-08507-5A phase I trial of a neoantigen-targeting personalized cancer vaccine led to durable and polyfunctional T cell responses and antitumour recognition, and was associated with no recurrence in patients with high-risk clear cell renal cell carcinoma.